Biotech Stocks Catching Fire: Sarepta Therapeutics (SRPT)
Sarepta Therapeutics Inc (NASDAQ:SRPT) shares are surging up and over their 50-day moving average, a gain of nearly 23% that takes SRPT back to levels not seen since November. The company, which develops RNA-based treatments for diseases including muscular dystrophy, is being bolstered by a positive note from Baird analysts on Tuesday reiterating a $102 price target.
Sarepta will next report results on Feb. 23 after the close. Analysts are looking for a loss of $1.10 per share on revenues of $5.6 million.